Pricing Log in Create free account
Saturday 17 October 2026 Export BNGO’s income statement to Excel — free account

Bionano Genomics, Inc.

BNGO Healthcare Medical Instruments & Supplies

Bionano Genomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.5 million, down 7.37% from fiscal 2024. In the quarter to June 2026, revenue grew 21.4%, EPS grew 67.8%, free cash flow fell 33.9% and total debt fell 1.91%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.25 0.12 −8.76%
Market cap
$16.1M
P/E
0.0×
Fwd P/E
−0.6×
Dividend yield
—
F-score
5/9
Altman Z
−14.26
Beneish M
−3.39
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Bionano Genomics, Inc. (BNGO) Business Profile

Updated before January 2025

Company Overview

Bionano Genomics, Inc. (BNGO) is a life sciences instrumentation company that specializes in genome analysis solutions. Founded in 2003 and headquartered in San Diego, California, Bionano Genomics has established itself as a leader in the field of structural variation detection and genome mapping. The company was founded by Dr. Han Cao, who developed the core technology behind Bionano’s flagship products. Over the years, Bionano has expanded its operations globally, serving academic, clinical, and pharmaceutical research markets.

The company’s leadership team includes Erik Holmlin, Ph.D., who serves as the President and Chief Executive Officer. Dr. Holmlin has extensive experience in the genomics and life sciences industries, having held leadership roles in various biotech companies. Other key executives include Chris Stewart, Chief Financial Officer, and Mark Oldakowski, Chief Operating Officer. Together, the leadership team has driven Bionano’s growth and innovation in the genomics space.

Core Business Segments

Bionano Genomics operates primarily in the genomics and life sciences sectors, offering products and services that enable researchers and clinicians to analyze structural variations in DNA. The company’s core business segments include:

1. Optical Genome Mapping (OGM)

Bionano’s flagship technology, Optical Genome Mapping, is powered by the Saphyr System. This platform enables researchers to detect large-scale structural variations in DNA with high accuracy and resolution. Key products under this segment include:

  • Saphyr System: A high-throughput platform designed for genome mapping and structural variation analysis. It is widely used in cancer research, genetic disease studies, and agricultural genomics.
  • Reagent Kits: Consumables required for sample preparation and genome mapping, including DNA isolation and labeling kits.

2. Data Analysis and Software Solutions

Bionano offers advanced software tools to complement its OGM technology. These tools enable users to analyze and interpret genomic data efficiently. Key offerings include:

  • Bionano Access: A cloud-based platform for managing and analyzing genome mapping data.
  • Bionano Solve: Proprietary software for structural variation detection and genome assembly.

3. Clinical Applications

Bionano is expanding its presence in the clinical diagnostics market by offering solutions for genetic disease diagnosis and cancer research. The company collaborates with clinical laboratories to integrate OGM into diagnostic workflows, enabling more accurate and comprehensive genetic analyses.

4. Services and Support

Bionano provides a range of services to support its customers, including:

  • Genome Analysis Services: Contract research services for customers who prefer to outsource their genome mapping projects.
  • Technical Support and Training: Comprehensive support and training programs to help users maximize the value of Bionano’s products.

Business Model

Bionano Genomics operates on a hybrid business model that combines product sales, consumables, and services. The company generates revenue through the following streams:

  1. Instrument Sales: Revenue from the sale of the Saphyr System and other genome mapping instruments.
  2. Consumables: Recurring revenue from the sale of reagent kits and other consumables required for genome mapping.
  3. Software Licenses: Subscription-based revenue from its data analysis and software solutions.
  4. Services: Revenue from genome analysis services and technical support.

This diversified revenue model ensures a steady income stream while fostering long-term customer relationships.

Strategic Direction

Bionano Genomics is focused on expanding its market presence and driving innovation in genome analysis. Key strategic initiatives include:

  1. Market Expansion: Bionano aims to increase its penetration in the clinical diagnostics market by promoting the adoption of OGM technology in genetic disease and cancer diagnostics.
  2. Product Development: The company is investing in research and development to enhance its existing products and develop new solutions for genome analysis.
  3. Global Reach: Bionano is expanding its global footprint by establishing partnerships with research institutions and clinical laboratories worldwide.
  4. Sustainability Goals: The company is committed to reducing its environmental impact by adopting sustainable practices in its operations and product development.

Competitive Landscape

Bionano Genomics operates in a highly competitive market, facing competition from companies in the genomics and life sciences sectors. Key competitors include:

  • Illumina, Inc.: A leader in next-generation sequencing (NGS) technologies.
  • Pacific Biosciences (PacBio): Known for its long-read sequencing platforms.
  • 10x Genomics: Specializes in single-cell and spatial genomics solutions.
  • Oxford Nanopore Technologies: Offers portable and scalable sequencing solutions.

Despite the competition, Bionano differentiates itself through its unique OGM technology, which provides unparalleled structural variation detection capabilities.

Risk Factors

Bionano Genomics faces several risks that could impact its business operations and financial performance. Key risk factors include:

  1. Market Dependence: The company relies heavily on the adoption of its OGM technology, which may face resistance from researchers and clinicians accustomed to traditional sequencing methods.
  2. Supply Chain Disruptions: Dependence on third-party suppliers for critical components and consumables poses a risk of supply chain disruptions.
  3. Regulatory Challenges: Compliance with regulatory requirements for clinical applications can be time-consuming and costly.
  4. Competition: Intense competition from established players in the genomics market could limit Bionano’s growth potential.

Recent Developments

Bionano Genomics has made significant strides in recent years, including:

  • Product Innovations: The company launched an upgraded version of the Saphyr System with enhanced throughput and accuracy.
  • Clinical Collaborations: Bionano partnered with leading clinical laboratories to integrate OGM into diagnostic workflows.
  • Global Expansion: The company established new distribution agreements to expand its presence in Asia and Europe.
  • COVID-19 Impact: While the pandemic initially disrupted operations, Bionano leveraged its technology to support COVID-19 research efforts.

Investment Considerations

Investors considering Bionano Genomics should weigh the following factors:

Strengths

  • Innovative Technology: Bionano’s OGM technology offers unique capabilities that set it apart from competitors.
  • Growing Market: The genomics market is expanding rapidly, driven by advancements in personalized medicine and genetic research.
  • Recurring Revenue: The sale of consumables and software licenses provides a steady income stream.

Risks

  • High Competition: The genomics market is highly competitive, with established players dominating the space.
  • Regulatory Hurdles: Delays in regulatory approvals for clinical applications could impact growth.
  • Financial Performance: As a relatively small company, Bionano may face challenges in achieving consistent profitability.

Conclusion

Bionano Genomics is a pioneering company in the field of genome analysis, offering innovative solutions for structural variation detection. With its unique OGM technology, the company is well-positioned to capitalize on the growing demand for advanced genomics tools. While challenges such as competition and regulatory hurdles remain, Bionano’s strategic initiatives and commitment to innovation provide a strong foundation for future growth.